Fever News and Research RSS Feed - Fever News and Research

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Fecal transplantation safe, effective for treating C. difficile in immunocompromised patients

Researchers have found that fecal transplantation is effective and safe for treating C. difficile in immunocompromised patients. This is the result of a study led by Colleen Kelly, M.D., a gastroenterologist in the Center for Women's Gastrointestinal Medicine at The Women's Medicine Collaborative. [More]
Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients. [More]
Viewpoints: Misreading Hobby Lobby; calmer climate for ACA; danger of tuberculosis, measles

Viewpoints: Misreading Hobby Lobby; calmer climate for ACA; danger of tuberculosis, measles

Liberals should spend less time lauding the dissents in last week's Hobby Lobby decision by the U.S. Supreme Court and more time reading them. [More]
Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Lysosomes are subcellular organelles that are present in most cells, with the major exception of red blood cells. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Priority actions needed to tackle the Ebola crisis in West Africa according to researchers in Sierra Leone

Priority actions needed to tackle the Ebola crisis in West Africa according to researchers in Sierra Leone

Researchers working in Sierra Leone suggest priority actions needed to tackle the ongoing Ebola crisis in West Africa. In a letter to The Lancet, the researchers call for improvements in access to diagnostic technologies and health-care resources, as well as improved disease surveillance and health communication. [More]
Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract. [More]
Scientists develop chip for detection of RNA strand of dengue fever virus

Scientists develop chip for detection of RNA strand of dengue fever virus

Scientists at the Center for Research and Advanced Studies (Cinvestav) in Mexico developed a chip (also known as cDNA microarray) that allows detection of the RNA strand of the dengue fever virus. [More]
Simple and hygienic measures can prevent campylobacter infections

Simple and hygienic measures can prevent campylobacter infections

In Switzerland, between 7000 and 8000 persons fall ill with a campylobacter infection annually. This makes it the most frequent bacterial disease transmitted through food. [More]
Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Multicenter trial aims to find safety, effectiveness of probiotics in infants with stomach flu

Consumers worldwide spend billions of dollars each year on probiotic foods and supplements. But studies evaluating probiotics - microorganisms believed to aid digestive health - have been limited. [More]
Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Tonsillectomy in adults improves quality of life

Tonsillectomy in adults improves quality of life

Tonsillectomy for recurrent pharyngitis in adults improves quality of life for the overwhelming majority of patients, report researchers. [More]
FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Laboratories acquires exclusive marketing rights for Aciphex Sprinkle in the U.S.

FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. [More]
MedicAlert Foundation announces free medical IDs for individuals living with Malignant Hyperthermia

MedicAlert Foundation announces free medical IDs for individuals living with Malignant Hyperthermia

MedicAlert Foundation is pleased to announce that individuals living with Malignant Hyperthermia (MH) are now eligible to receive free medical IDs and live 24/7 emergency response services as the result of a grant obtained through the Sandi Ida Glickstein Fund at the Malignant Hyperthermia Association of the United States. [More]
Lassa virus uses two-step process to invade cells, shows study

Lassa virus uses two-step process to invade cells, shows study

Scientists have discovered that the Lassa virus, which is endemic to West Africa, uses an unexpected two-step process to enter cells. [More]
Tips to protect children from summer bugs

Tips to protect children from summer bugs

Mike Gittelman, MD, Co-Director, Comprehensive Children's Injury Center and the experts at Cincinnati Children's Hospital Medical Center want to make sure that families and children stay safe while playing outdoors this summer. [More]
Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). [More]

Researchers review effectiveness of RDTs in diagnosing visceral leishmaniasis

Researchers from the Cochrane Infectious Disease Group, co-ordinated through the editorial base in LSTM, conducted an independent review into the effectiveness of rapid diagnostic tests in diagnosing patients with visceral leishmaniasis (VL), published in The Cochrane Library today. [More]
Entomologists develop chromosome map to find ways to prevent dengue fever, yellow fever

Entomologists develop chromosome map to find ways to prevent dengue fever, yellow fever

Virginia Tech entomologists have developed a chromosome map for about half of the genome of the mosquito Aedes agypti, the major carrier of dengue fever and yellow fever. [More]